Oral agents in managing diabetes mellitus in children and adolescents

Pediatric Clinics of North America

Volumn 52, Issue 6, 2005, Pages 1689-1703

  Jacobson Dickman, Elka ^a   Levitsky, Lynne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM ANTAGONIST; CHLORPROPAMIDE; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBURIDE; GLIPIZIDE; GLYCOSIDASE INHIBITOR; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; NICOTINAMIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PEDIATRICS; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; CARBAMATES; CHILD; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PIPERIDINES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 27844494755     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2005.07.008     Document Type: Review

References (44)

1. American Diabetes Association Type 2 diabetes in children and adolescents Pediatrics 105 3 Pt 1 2000 671 680
2. D. Nathan Long-term complications of diabetes mellitus N Engl J Med 328 23 1993 1676 1685
3. M. Henricsson, L. Nystrom, and G. Blohme The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS) Diabetes Care 26 2 2003 349 354
4. A.I. Adler, I.M. Stratton, and H.A. Neil Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study BMJ 321 7258 2000 412 419
5. G. Uwaifo, and R. Ratner Novel pharmacologic agents for type 2 diabetes Endocrinol Metab Clin N Am 34 2005 155 197
6. J. Skyler, J. Krischer, and J. Wolfsdorf Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1 Diabetes Care 28 2005 1068 1076
7. B. Ergun-Longmire, J. Marker, and A. Zeidler Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes Ann N Y Acad Sci 1029 2004 260 277
8. A. Crino, R. Schiaffini, and S. Manfrini A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX) Eur J Endocrinol 150 2004 719 724
9. E. Ortqvist, E. Bjork, and M. Wallensteen Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes Diabetes Care 27 2004 2191 2197
10. M. Rios Acarbose and insulin therapy in type 1 diabetes mellitus Eur J Clin Invest 24 Suppl 3 1994 36 39
11. D. Nathan Clinical practice: initial management of glycemia in type 2 diabetes mellitus N Engl J Med 347 17 2002 1342 1349
12. H. Ilkova, B. Glaser, and A. Tunckale Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment Diabetes Care 20 9 1997 1353 1356
13. J. Porter, and T. Barrett Acquired non-type 1 diabetes in childhood: subtypes, diagnosis, and management Arch Dis Child 89 12 2004 1138 1144
14. American Diabetes Association Standards of medical care for patients with diabetes mellitus: position statement Diabetes Care 22 1S 1999 32S 41S
15. R. De Fronzo Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 4 1999 281 303
16. M. Riddle Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulin, and combinations Enocrinol Metab Clin N Am 34 2005 77 98
17. C.J. Baily Biguanides and NIDDM Diabetes Care 15 6 1992 755 772
18. M. Tiikkainen, A. Hakkinen, and E. Korshennikova Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169 2176
19. G. Zhou, R. Myers, and Y. Li Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
20. A. Caballero, S. Arora, and R. Saouaf Micro and macro-vascular reactivity is reduced in subjects at risk for type 2 diabetes Diabetes 48 1999 1856 1862
21. R. De Fronzo, and A. Goodman Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group N Engl J Med 333 9 1995 541 549
22. K. Jones, S. Arslanian, and V. Peterokova Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial Diabetes Care 25 1 2002 89 94
23. B. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 4 1998 507 514
24. A. Vidal-Puig, R. Considine, and M. Jimenez-Linan Peroxisome-proliferator activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids J Clin Invest 99 1997 2416 2422
25. T. Combs, A. Berg, and S. Obici Endogenous glucose production is inhibited by adipose-derived protein Acrp30 J Clin Invest 2001 2001 1875 1881
26. S. Inzucchi, D. Maggs, and G. Spollett Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 338 13 1998 867 872
27. M. Khan, J. St Peter, and J. Xue A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone Diabetes Care 25 4 2002 708 711
28. R. Nesto, D. Bell, and R. Bonow Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 1 2004 256 263
29. S. Aronoff, S. Rosenblatt, and S. Braithwaite Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes Care 23 11 2000 1605 1611
30. L. Groop Sulfonylureas in NIDDM Diabetes Care 15 6 1992 737 754
31. E. Haupt, F. Laube, and H. Loy Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides Med Klin 72 38 1977 1529 1536
32. Group UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
33. Group UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 9131 1998 837 853
34. E. Horton, C. Clinkingbeard, and M. Gatlin Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes Diabetes Care 23 11 2000 1660 1665
35. J. Chiasson, R. Josse, and J.A. Hunt The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial Ann Intern Med 121 12 1994 928 935
36. G. Viberti, S. Kahn, and D. Greene A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes Diabetes Care 25 10 2002 1737 1743
37. C. Torn, M. Landin-Olsson, and J. Ostman Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds Diabetes Metab Res Rev 16 6 2000 442 447
38. E. Hathout, W. Thomas, and M. El-Shahawy Diabetic autoimmune markers in children and adolescents with type 2 diabetes Pediatrics 107 2001 E102
39. L. Hermann, B. Schersten, and P. Bitzen Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study Diabetes Care 17 10 1994 1100 1109
40. J. De Jager, A. Kooy, and P. Lehert Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized placebo-controlled trial J Intern Med 257 2005 100 109
41. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 14 1993 977 986
42. D. Nathan Some answers, more controversy, from UKPDS: United Kingdom Prospective Diabetes Study Lancet 352 9131 1998 832 833
43. National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication 98-4080 1998 National Institutes of Health Bethesda (MD)
44. American Diabetes Association Management of dyslipidemia in children and adolescents with diabetes Diabetes Care 26 2003 2194 2197